Evidence with currently epidemic Sars-cov-2
There is some evidence demonstrating the efficacy of PT in COVID-19 patients. In a pilot study conducted in China on 10 severe COVID-19 patients, an improvement in clinical symptoms was recorded in all patients within a few days of PT administration (15); in 7 patients, transfusion of PT was associated with a decrease in viral load. Five cases of COVID-19 severe patients were described , who reported a rapid improvement in clinical status following transfusion, with convalescent plasma (IgG titers SARS-CoV-2 >1000) (16). These two studies also have a limited sample. In order to assess the effectiveness of plasma convalescence therapy, another study conducted in patients with severe COVID-19 showed that PT resulted in symptom alleviation, changes in radiological abnormalities and laboratory tests and that no obvious adverse effects were observed during treatment. (17) In addition, a review was carried out to assess the effectiveness of PT in patients with COVID-19. The results reported that PT in patients with COVID-19 can reduce mortality in critical patients, the increase in neutralizing antibody titers and the disappearance of SARS-CoV-2 RNA was observed in almost all patients after therapy, a reduction in clinical symptoms after administration of convalescent plasma. Based on the results of this review, although data are limited, PT in the COVID-19 patient appears safe, clinically effective and reduces mortality. (18)